All In Biotech

Drug Trial Radar · NCT06422936

Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)

SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Actual

Start

May 27, 2024

Primary completion

Dec 2026

Study completion Jun 2028

Sponsor

Lead sponsor
Highlight TherapeuticsIndustry
Sponsor type
Industry
First posted
May 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability, pharmacodynamics and preliminary efficacy of intra-lesional BO-112 in patients with resectable primary low and high risk basal cell carcinoma. * primary endpoint is composite visual and pathological response \[at surgery\] on patient level as assessed by central review * secondary endpoints are 1. Occurrence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation or death on patient level. 2. Pathological response \[at surgery\] on patient level assessed by the investigator and central review, respectively, and visual response \[during the study and at surgery\] on patient level assessed by the investigator and central review, respectively.

Conditions

  • Basal Cell Carcinoma

Interventions

  • BO-112Drug

    Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Visual and Pathological ResponseTime frame: at surgery

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Soroka Medical Center

    Beersheba, Israel

  • Rambam Medical Center

    Haifa, Israel

  • Hadassah Ein Kerem Medical Center

    Jerusalem, Israel

  • Kaplan Medical Center

    Rehovot, Israel

  • Hospital Clínic Barcelona

    Barcelona, Spain

  • Hospital de Basurto

    Bilbao, Spain

  • Clínica Universitaria de Navarra (CUN)

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Complejo Asistencial Universitario de Salamanca

    Salamanca, Spain

  • Instituto Valenciano de Oncología (IVO)

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.